Affordable Access

deepdyve-link deepdyve-link
Publisher Website

Weekly paclitaxel in the treatment of recurrent ovarian cancer.

Authors
Type
Published Article
Journal
Nature Reviews Clinical Oncology
1759-4782
Publisher
Nature Publishing Group
Publication Date
Volume
7
Issue
10
Pages
575–582
Identifiers
DOI: 10.1038/nrclinonc.2010.120
PMID: 20683437
Source
Medline
License
Unknown

Abstract

Weekly paclitaxel is a highly active and well tolerated regimen that is increasingly being adopted for the treatment of relapsed ovarian cancer. This regimen is usually administered at 80-90 mg/m(2)/week, and the use of a 1 h infusion helps minimize myelosuppression. When compared with the 3-weekly schedule, weekly paclitaxel is better tolerated, with a reduced frequency of grade 3-4 toxic effects. Single-agent weekly paclitaxel for relapsed ovarian cancer yields response rates in the range of 20-62%; however, response duration can be short. Responses to weekly paclitaxel have been observed in patients whose tumors are resistant to 3-weekly paclitaxel. The level of activity of weekly paclitaxel for relapsed disease has led to its detailed evaluation in the first-line setting, and interest has been enhanced by the results of a Japanese Gynecological Oncology Group study that demonstrated a survival advantage for weekly paclitaxel compared with 3-weekly paclitaxel in combination with carboplatin as initial treatment. The enhanced efficacy of weekly paclitaxel may be due to greater drug exposure, a direct antiangiogenic effect, or both. Current research topics include the combination of weekly paclitaxel with molecular-targeted agents and the use of molecular profiling to better select patients for treatment.

Statistics

Seen <100 times